产品简要
公司名称 :
ACROBiosystems
产品类型 :
其他
产品名称 :
Human EGFRvIII-coupled Magnetic Beads
目录 :
MBS-K020
规格 :
10毫克, 2毫克
价格 :
2500美元, 800美元
更多信息或购买 :
产品信息
公司名称 :
ACROBiosystems
产品类型 :
Beads
目录 :
MBS-K020
产品名称 :
Human EGFRvIII-coupled Magnetic Beads
规格 :
10毫克, 2毫克
价格 :
2500美元, 800美元
规格&价格 :
$800/2mg,$2500/10mg (5mg × 2)
靶标 :
EGFRvIII
宿主物种 :
人类
研究 :
For Research Use Only
配方 :
想要获得更多细节请与我们联系信息
重组 :
See Certificate of Analysis (CoA) for detailed instruction.
储存 :
Upon receipt, please store the beads at -20℃. The shelf life is 6 months at -20 ℃. Please avoid more than 3 freeze-thaw cycles. Immediate use after reconstitution is highly recommended.
背景 :
The Human EGFRvIII-coupled Magnetic Beads is produced by coupling biotinylated EGFRvIII protein to streptavidin-conjugated magnetic beads. Because Streptavidin (SA) has an extraordinarily high affinity for biotin with a dissociation constant (Kd) on the order of 10-14 mol/L, the biotinylated protein can bind to the SA beads irreversibly. The pre-coupled beads are ready to use for capturing anti-EGFRvIII antibody from your sample with high specificity.
更多信息或购买 :
公司信息
ACROBiosystems
1 Innovation Way Newark, DE 19711, USA
order@acrobiosystems.com
http://www.acrobiosystems.com1-800-810-0816
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.